Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Hezhe Lu,Shujing Liu,Gao Zhang,Lawrence N. Kwong,Yueyao Zhu,John P. Miller,Yi Hu,Wenqun Zhong,Jingwen Zeng,Lawrence Wu,Clemens Krepler,Katrin Sproesser,Min Xiao,Wei Xu,Giorgos C. Karakousis,Lynn M. Schuchter,Jeffery Field,Paul J. Zhang,Meenhard Herlyn,Xiaowei Xu,Wei Guo

DOI: https://doi.org/10.1016/j.celrep.2016.04.073

IF: 8.8

2016-01-01

Cell Reports

Abstract:Melanoma patients with oncogenic BRAFV600E mutation have poor prognoses. While the role of BRAFV600E in tumorigenesis is well established, its involvement in metastasis that is clinically observed in melanoma patients remains a topic of debate. Here, we show that BRAFV600E melanoma cells have extensive invasion activity as assayed by the generation of F-actin and cortactin foci that mediate membrane protrusion, and degradation of the extracellular matrix (ECM). Inhibition of BRAFV600E blocks melanoma cell invasion. In a BRAFV600E-driven murine melanoma model or in patients’ tumor biopsies, cortactin foci decrease upon inhibitor treatment. In addition, genome-wide expression analysis shows that a number of invadopodia-related genes are downregulated after BRAFV600E inhibition. Mechanistically, BRAFV600E induces phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics and matrix metalloprotease secretion, respectively. Our results provide support for the role of BRAFV600E in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.